Sign up to save your podcasts
Or
Share FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.
Key topics included:
• The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3.
• Study design and findings from the EPCOR FL1 trial.
• Step-up dosing schedule and its implications for patient management.
• Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• The role of minimal residual disease (MRD) and ctDNA in treatment decisions.
Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.
Key topics included:
• The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3.
• Study design and findings from the EPCOR FL1 trial.
• Step-up dosing schedule and its implications for patient management.
• Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• The role of minimal residual disease (MRD) and ctDNA in treatment decisions.
Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Mayo Clinic Talks
297 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,357 Listeners
Core IM | Internal Medicine Podcast
1,142 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners